Introduction
============

Receptor tyrosine kinases (RTKs) and their ligand have been found to be genetically altered and overexpressed in various human cancers and therefore considered as therapeutic targets for cancer \[[@b1-crt-2018-052]\]. The mesenchymal-epithelial transition factor (MET) and its ligand, hepatocyte growth factor, are required for organ regeneration and tissue damage repair, which resemble the pathological process of tumor invasion \[[@b2-crt-2018-052]\]. Accordingly, aberrant activation of MET signaling cascades including multiple downstream effector pathways such as signal transducer and activator of transcription 3 (STAT3), rat sarcoma (RAS)/mitogen-activated protein kinase (MAPK), and phosphoinositide-3-kinase (PI3K)/AKT, occurs in many types of cancer; receptor crosstalk with other RTKs also has been observed \[[@b3-crt-2018-052]\]. *MET* can be inappropriately activated via mutations, amplification and/or overexpression \[[@b4-crt-2018-052]-[@b6-crt-2018-052]\].

Lung cancer is the leading cause of cancer-related death worldwide. Genetic alteration of *MET* has been detected in non-small cell lung cancer (NSCLC) and *MET* amplification has been reported in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naïve NSCLC patients, with a prevalence of 1.4% to 21% \[[@b7-crt-2018-052]-[@b10-crt-2018-052]\]. In NSCLC, amplification of *MET* results in constitutive kinase activity in the absence of its ligand; overexpression acts as an oncogenic driver and activator of downstream signaling pathways such as the PI3K/AKT pathway \[[@b5-crt-2018-052],[@b11-crt-2018-052]\].

MET presents an attractive therapeutic target for cancers including NSCLC and amplification of *MET* is an excellent predictive marker of sensitivity to MET-TKIs \[[@b6-crt-2018-052],[@b9-crt-2018-052],[@b12-crt-2018-052],[@b13-crt-2018-052]\]. Capmatinib (INC280, Novartis) is a highly potent and selective small molecule inhibitor of MET. The selectivity of capmatinib is \> 10,000-fold for MET in human kinase assays \[[@b14-crt-2018-052]\]. In addition, capmatinib demonstrated potent inhibition of cell growth and MET-dependent survival signaling activity in MET-dependent cell lines and patient tumor \[[@b6-crt-2018-052],[@b15-crt-2018-052]\]. Although a dramatic response to capmatinib was observed in *MET*-amplified NSCLC \[[@b15-crt-2018-052]\], acquired resistance to capmatinib is inevitable. Therefore, *in vitro* NSCLC cell line models are useful to identify the molecular mechanisms of resistance to capmatinib and establish strategies to overcome it.

In this study, we have established *MET*-amplified NSCLC cell lines that showed acquired resistance to capmatinib and evaluated its resistance mechanisms. We demonstrated that capmatinib-resistant NSCLC cells were dependent on alternative pathway activation. Despite acquired resistance, the combined inhibition of EGFR or PIK3CA dramatically suppresses cell proliferation and downstream signals of capmatinib-resistant NSCLC cell lines, which suggested that this combination could be an effective therapeutic strategy against MET-TKI resistance in NSCLC patients.

Materials and Methods
=====================

1. Cell lines and drugs
-----------------------

The EBC-1 cell line, which is an NSCLC cell line that harbors a *MET* amplification, was purchased from the JCRB Cell Bank (Osaka, Japan). Capmatinib-resistant EBC-1 cell lines (EBC-CR1, -CR2, and -CR3) were established via stepwise exposure to capmatinib at final concentrations of 1.5, 2.2, and 2.4 μmol/L, respectively and were not selected from one cell without cloning. EBC-CR1, -CR2, and -CR3 cells were maintained in 1 μmol/L of capmatinib over 2 months and selected due to diverse resistance mechanisms; these are referred to as capmatinib-resistant cell lines. All cell lines were incubated in RPMI1640 medium (Gibco, Carlsbad, CA) with 10% FBS, 2 mmol/L of L-glutamine (Gibco), and 1% penicillin/streptomycin (Gibco) in a 37˚C incubator. Capmatinib (MET inhibitor), crizotinib (anaplastic lymphoma kinase/MET inhibitor), afatinib (irreversible EGFR inhibitor), BYL719 (PI3Kα inhibitor), PD1730-74 (fibroblast growth factor receptor \[FGFR\] inhibitor), and BGJ398 (FGFR inhibitor) were purchased from Selleck Chemicals (Boston, MA). Capmatinib was prepared at 5 mmol/L and the other drugs were prepared as 10 mmol/L stock solutions in 100% dimethyl sulfoxide. Recombinant heparin-binding EGF-like growth factor (HBEGF) was purchased from Prospec (East Brunswick, NJ). All cell lines used in this study were authenticated by Short Tandem Repeat STR analysis using PowerPlex kit (Promega, Madison, WI).

2. Cell viability and apoptosis assays
--------------------------------------

To determine the sensitivity of the cell lines to these inhibitors *in vitro*, cells were seeded into 96-well microplates at 5,000 cells/well and incubated in medium for 24 hours prior to exposure to the drugs. The cells were incubated with serial dilutions of the inhibitors in a final volume of 200 μL/well for 72 hours. After the 72-hour incubation, Ez-cytox (Dogen, Seoul, Korea) was added to each well and the plates were incubated for 3 hours in a 37°C incubator. The optical density was measured at a test wavelength of 450 nm using an Eon Microplate Spectrophotometer (Biotech, Winooski, VT). The IC~50~ values were calculated by Sigma Plot 12 (Hulinks, Tokyo, Japan). Cells were seeded in 6 well plates at a density of 5×10^5^ per wells for cell cycle and apoptosis analyses. Twenty-four hours later, the cells were treated with inhibitors for 72 hours. Both adherent and floating cells were harvested and stained with propidium iodide (1.0 mg/mL) and RNase A (10 mg/mL) (Sigma-Aldrich, St. Louis, MO). Quantification for the cell-cycle distribution and the sub-G1 population was performed by flow cytometric analysis using BD FACSCalibur (BD, East Rutherford, NJ) and ModFit LT verity software (Verity Software House Inc., Topsham, ME).

3. Western blot analysis and human phospho-RTK array
----------------------------------------------------

EBC-1 parental and EBC-CR1, -CR2, and -CR3 cell lines, grown to adequate densities in 6-well plates, were treated for 2 hours with capmatinib alone, 24 hours with the combination of capmatinib and afatinib, or 24 hours with BYL719. Rabbit monoclonal antibodies to detect phospho-MET (Tyr-1234/1235), phospho-EGFR (Tyr1068), phospho-STAT3 (Tyr705), phospho-AKT (Ser473), total MET, total EGFR, total AKT, total p44/42 MAPK, and glyceraldehyde 3-phosphate dehydrogenase, and mouse monoclonal antibody to detect total STAT3 were purchased from Cell Signaling Technology (Danvers, MA). Mouse anti-phospho-p44/42 MAPK (Thr-202/Tyr204) was purchased from Santa Cruz Biotechnology (Dallas, TX). Western blotting chemiluminescence reagents were purchased from GE Healthcare (Chicago, IL). All antibodies and reagents were used according to the manufacturers' instructions.

Phospho-RTK was detected using the Human Phospho-RTK Array kit (R&D Systems, Minneapolis, MN). An LAS-3000 imaging system (Fuji Photo Film Co., Stanford, CT) was used for image analysis.

4. Co-immunoprecipitation
-------------------------

Cells were washed once with modified Dulbecco's phosphate-buffered saline and lysed in buffer containing 0.025 M Tris, 0.15 M NaCl, 0.0001 M EDTA, 1% NP-40, and 5% glycerol (pH 7.4). Protein G/A agarose resin (Thermo Fisher Scientific, Waltham, MA) was incubated for 2 hours with rabbit monoclonal anti-MET antibody (Cell Signaling Technologies), anti-EGFR antibody (Cell Signaling Technologies) or rabbit IgG control (Invitrogen, Carlsbad, CA) as a negative control and cell lysate at 1 mg of protein was mixed with antibody-coupled resin (Cell Signaling Technologies) overnight at 4°C. Co-immunoprecipitation was performed using the Pierce Co-IP Kit (Thermo Fisher Scientific). Immunoprecipitates were washed, eluted, and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Western blot was performed as described above.

5. Genomic DNA analysis
-----------------------

Gene copy numbers were determined by quantitative polymerase chain reaction (PCR). Genomic DNA (gDNA) was extracted from cell lines using the Exgene Cell SV Kit (Geneall Biotechnology, Seoul, Korea). Quantitative PCR was used to determine the gene copy number as follows: gDNA was amplified with specific primers ([S1 Table](#SD1-crt-2018-052){ref-type="supplementary-material"}) and SYBR Green PCR Master Mix (Applied Biosystems, Waltham, MA) using the GeneAmp PCR System (Applied Biosystems); images were captured with the Gel Logic 200 Imaging System (Kodak, Rochester, NY). Gene copy numbers were extrapolated from an external standard curve generated by serial dilutions of human gDNA (Merck Millipore, Darmstadt, Germany). The PCR products were purified using the PCR Purification Kit (Invitrogen), and sequenced by bidirectional Sanger sequencing.

6. Quantitative reverse transcription PCR and 3′-mRNA sequencing
----------------------------------------------------------------

Total RNA was extracted from EBC-1 parental and resistant cell lines using the RNA Mini Kit (Invitrogen) and reverse transcribed using Superscript III Reverse Transcriptase (Invitrogen). The StepOnePlus Real-Time PCR System (Applied Biosystems) was used for amplification of cDNA and quantitative real-time reverse transcriptase polymerase chain reaction was performed using the SYBR Green PCR Master Mix (Applied Biosystems) with specific primers ([S2 Table](#SD2-crt-2018-052){ref-type="supplementary-material"}). Relative gene expression was calculated using the ΔΔCt (cycle threshold) method with β-actin as the reference gene. Sequencing of the 3′-mRNA was performed using Quantseq technology (Lexogen, Vienna, Austria). RNA was extracted from EBC-1 and resistant cell lines as described above. Hierarchical clustering was analyzed on log2-fold changes in gene expression using the MultiExperiment Viewer (Dana Farber Cancer Institute, Boston, MA). Normalized read counts were calculated as (log2) \> 6, and genes with an adjusted p \< 0.05 were considered significantly differentially expressed.

7. Statistical analysis
-----------------------

Data are presented as mean±standard deviation of independently performed experiments. Statistical analyses were evaluated using Sigma Plot 12 (Systat Software Inc., San Jose, CA). Student\'s t tests were used to indicate statistically significant differences (p \< 0.05).

Results
=======

1. Establishment of EBC-1 cells with acquired resistance to capmatinib
----------------------------------------------------------------------

EBC-1 cells were derived from NSCLC cell lines harboring *MET* amplification and showing high sensitivity to MET-TKIs. To explore the molecular mechanisms of resistance to MET-TKIs, we used capmatinib, an MET inhibitor that is currently being studied in clinical trials. Using the EBC-1 cell line, we established total three cell lines resistant to capmatinib (EBC-CR1, -CR2, and -CR3) by stepwise exposure to capmatinib from 10 nM to final concentrations of 1.5, 2.2, and 2.4 μmol/L, respectively to observe various resistant mechanisms. The EBC-CR3 cell line was derived from the EBC-CR1 cell line by continuous exposure to a higher concentration of capmatinib during additional 3 months ([S3A Fig.](#SD3-crt-2018-052){ref-type="supplementary-material"}). First, we evaluated the sensitivity of the all three resistant cell lines to capmatinib by cell viability assay. The MET-TKIs were not toxic to the resistant cell lines (IC~50~, \> 10 μmol/L on EBC-CR1--3 cells and 3.70±0.10 nmol/L on EBC-1 cells; and sub-G1, 18.15±3.31% on EBC-CR1, 8.37±4.61% on EBC-CR2, 12.17±3.6% on EBC-CR3, and 61.22±4.78% on EBC-1 cells) ([Fig. 1A](#f1-crt-2018-052){ref-type="fig"}, [S3B Fig.](#SD3-crt-2018-052){ref-type="supplementary-material"}). Next, we confirmed the decrease of *MET* gene copy number by qPCR in resistant cell lines, which was accompanied by downregulation of MET phosphorylation ([Fig. 1B](#f1-crt-2018-052){ref-type="fig"}). These results suggested that capmatinib strongly affected not only kinase activity but also *MET* copy number, which indicated its potent efficacy against MET-dependent tumors. Also, there were no additional *MET*-activating mutations identified by Sanger sequencing (data not shown).

In resistant cell lines, complete inhibition of MET phosphorylation by capmatinib demonstrated that there were no *MET* mutations that prevented the binding of capmatinib. Although complete inhibition of MET kinase was observed, phosphorylation of AKT and ERK1/2 were not completely inhibited in the resistant cell lines by a single treatment with capmatinib ([Fig. 1C](#f1-crt-2018-052){ref-type="fig"}). These results suggest that 'main' survival pathways in resistant cells change from MET signal to other alternative kinase pathway.

2. Acquired resistant mechanisms to capmatinib associated with EGFR kinase pathway
----------------------------------------------------------------------------------

To identify alternative survival pathways of capmatinib resistance, EBC-1, EBC-CR1, -CR2, and -CR3 cells were screened for gene expression by 3′-mRNA sequencing. First, we analyzed expression of RTK-related genes by hierarchical clustering. RTK-related genes were stratified into several clusters and almost 20% of RTK-related genes were significantly upregulated in the resistant cell lines ([Table 1](#t1-crt-2018-052){ref-type="table"}, [Fig. 1D](#f1-crt-2018-052){ref-type="fig"}). According to the results of 3\' mRNA sequencing, MET mRNA expression was slightly decreased and EGFR mRNA expression was increased in EBC-CR1, -CR2, and -CR3 compared to the parental cell line ([Table 1](#t1-crt-2018-052){ref-type="table"}). We then confirmed increased EGFR protein phosphorylation compared to multiple RTKs in the resistant cell lines but observed no change in *EGFR* copy number ([S1C and S3D Fig.](#SD3-crt-2018-052){ref-type="supplementary-material"}). The mostly upregulated genes were *KIT* and *EFEMP1* ([Table 1](#t1-crt-2018-052){ref-type="table"}, [Fig. 1D](#f1-crt-2018-052){ref-type="fig"}). Although *KIT* mRNA was highly upregulated, KIT activation was not observed in phospho-RTK array ([S3C Fig.](#SD3-crt-2018-052){ref-type="supplementary-material"}). In contrast, EGFR signal was activated at both mRNA and protein levels. In addition, EFEMP1 that binds to EGFR can activate the downstream signals and eventually increase EGFR signal \[[@b16-crt-2018-052]\]. These results suggested that the EGFR signaling pathway might be an alternative pathway for MET. Although EGFR activation was increased in all resistant cell lines, cell viability assay to afatinib showed that only EBC-CR1 remained sensitive to afatinib alone ([Fig. 2A](#f2-crt-2018-052){ref-type="fig"}). Interestingly, capmatinib inhibited EGFR kinase phosphorylation in EBC-1 cells. To determine the mechanism of EGFR pathway activation in the EBC-CR1 cell line, we tested the expression of multiple EGFR ligands (including epidermal growth factor \[EGF\], amphiregulin, epiregulin, transforming growth factor-α, and HBEGF) and observed that HBEGF expression was elevated in EBC-CR1 cells ([Fig. 2B](#f2-crt-2018-052){ref-type="fig"}, [S4A Fig.](#SD4-crt-2018-052){ref-type="supplementary-material"}). To further explore the role of HBEGF in EGFR activation, we added exogenous HBEGF to the EBC-1 and EBC-CR1 cell lines and found that HBEGF was sufficient to rescue to MET inhibition in the MET-dependent NSCLC cell line, EBC-1 ([S3E Fig.](#SD3-crt-2018-052){ref-type="supplementary-material"}). In EBC-CR1, cultures with HBEGF were more resistant to EGFR inhibition than those without ligand (p \< 0.01) ([S3F Fig.](#SD3-crt-2018-052){ref-type="supplementary-material"}). Unlike the parental cell line, a single treatment with afatinib effectively inhibited phosphorylation of EGFR, AKT, and ERK1/2 despite persistent MET kinase activation ([Fig. 2C](#f2-crt-2018-052){ref-type="fig"}). As a result, EGFR activation was highly dependent on HBEGF as the main survival signal in EBC-CR1 cells.

3. Increased MET and EGFR heterodimerization can cause acquired resistance to capmatinib
----------------------------------------------------------------------------------------

In contrast to EBC-CR1 cells, in EBC-CR2 cells, the combined blockade of MET and EGFR kinase significantly abolished phosphorylation of the downstream signaling molecules, AKT and ERK1/2 ([Fig. 3A](#f3-crt-2018-052){ref-type="fig"}). While activation of both MET and EGFR kinase was diminished in the parental cell line, EGFR phosphorylation was increased in EBC-CR2 cells by capmatinib treatment and MET phosphorylation was increased by afatinib. Intriguingly, EBC-CR2 cells displayed more dominant MET-EGFR heterodimers than the parental cell line ([Fig. 3B](#f3-crt-2018-052){ref-type="fig"}). To determine the efficacy of combined treatment with capmatinib and afatinib, we performed the cell viability assay to compare the effect of capmatinib, afatinib, and their combination in EBC-CR2 cells. We observed that the IC~50~ was lower in the cells treated with the combination compared to either compound alone, which suggested that capmatinib and afatinib synergistically inhibited cell proliferation ([Fig. 3C](#f3-crt-2018-052){ref-type="fig"}). These results indicated that dual blockade of MET and EGFR obstructed the MET-mediated EGFR survival signal caused by MET and EGFR heterodimerization. Accordingly, the MET-EGFR heterodimer is a much more dominant form of activated EGFR kinase, which is the main survival signal in EBC-CR2 cells.

4. Acquired resistance to EGFR TKI beyond capmatinib resistance
---------------------------------------------------------------

Despite continuous exposure of the EBC-CR3 cell line (derived from EBC-CR1 cells) to capmatinib but not EGFR-TKI resulted in the loss of sensitivity to afatinib in the cell viability assay ([Fig. 4A](#f4-crt-2018-052){ref-type="fig"}). In Western blot, EBC-CR3 showed a complete block of EGFR or MET activation, but persistent AKT phosphorylation after afatinib treatment ([S5B Fig.](#SD5-crt-2018-052){ref-type="supplementary-material"}). We performed qRT PCR and Sanger sequencing to investigate the mechanism underlying *EGFR*-dependent resistance to afatinib. We found that *PIK3CA* mRNA expression was increased and gene copy number was amplified in EBC-CR3 cells, which was unlike what we observed in the other cell lines ([Fig. 4B](#f4-crt-2018-052){ref-type="fig"}, [S5C Fig.](#SD5-crt-2018-052){ref-type="supplementary-material"}); however, we did not find any hot spot mutations in *PIK3CA* (data not shown). *PIK3CA* amplification was observed frequently and might play a pathogenic role in lung cancer, especially squamous cell carcinoma \[[@b17-crt-2018-052]\]; thus we hypothesized that *PIK3CA* amplification is acquired resistant mechanism to capmatinib. To confirm this hypothesis, we tested the efficacy of BYL719 on PIK3CA inhibition in EBC-CR3 cells, because this molecular target of BYL719 had been reported previously. \[[@b18-crt-2018-052]\] As a result, we showed resistance after a single treatment with BYL719; however, the cells with concurrent EGFR overexpression were sensitive to BYL719 in the presence of afatinib in the cell viability assay (IC~50~ for BYL719, 140.84±19.65 nmol/L) ([Fig. 4A](#f4-crt-2018-052){ref-type="fig"}). Although EBC-1 and EBC-CR2 cells were resistant to combined treatment of BYL719 and afatinib, it showed additive effect on EBC-CR1 cells ([S6A Fig.](#SD6-crt-2018-052){ref-type="supplementary-material"}). In addition, the combination of BYL719 with afatinib effectively inhibited phosphorylation of AKT, despite the persistence of the MET signal ([Fig. 4C](#f4-crt-2018-052){ref-type="fig"}), and inactivation of RAS/MAPK pathway (data not shown). The combined treatment incompletely inhibited AKT phosphorylation on EBC-1 and -CR2 ([S6B Fig.](#SD6-crt-2018-052){ref-type="supplementary-material"}). Although one or more colony might be formed in EBCCR3 cells, there was no other genetic modification in other colonies except *PIK3CA* amplification. These results demonstrated that wild-type *PIK3CA* amplification could be an additional mechanism of resistance to EGFR-TKI in capmatinib-resistant cancers; however, the combined therapy effectively overcame the resistance to TKIs in a *MET*-independent manner in the presence of additional genetic alterations.

Discussion
==========

In this study, we observed EGFR mRNA overexpression without the presence of an *EGFR* activating mutation or amplification, as described above. These findings suggested that common resistance to capmatinib occurred via activation of signaling pathways outside of MET kinase, rather than via genetic alteration of specific genes. Furthermore, partial or complete engagement of the EGFR signal was one resistance mechanism against capmatinib, which indicated a preferable alternative signaling pathway in MET-dependent cancer cells.

Previous clinical research reported de novo *MET* amplification in NSCLC patients. *MET* amplification may be druggable targets for MET-TKIs on the basis of preclinical and clinical findings \[[@b19-crt-2018-052]-[@b21-crt-2018-052]\]. Therefore, preclinical and clinical trials of MET-TKIs have been reported for several cancers. Capmatinib, which is currently in clinical trials, is a very selective and potent MET-specific agent for MET-dependent cancer \[[@b6-crt-2018-052],[@b13-crt-2018-052],[@b15-crt-2018-052]\]. However, rapid development of acquired resistance to MET-TKIs has been crucial limitation to efficacy. Nonetheless, only a few resistance mechanisms of MET-TKIs have been elucidated up until now. Therefore, it is important to identify the underlying mechanisms of MET-TKIs resistance through molecular studies and establish effective therapeutic strategies to manage acquired resistance. Although an *in vivo* model is important, *in vitro* cancer cell lines can provide a valuable model system to investigate resistance mechanisms. Here, we have used this *in vitro* strategy to identify molecular resistance mechanisms of capmatinib in *MET*-amplified NSCLC cell lines.

MET positively regulates EGFR signal pathway via multiple mechanisms, so EGFR phosphorylation decrease by selective MET-TKI, capmatinib in *MET*-amplified NSCLC cell lines \[[@b6-crt-2018-052]\]. The EGFR signal has been reported as a preferable bypass mechanism for MET kinase, and the combination of EGFR-TKI with MET-TKI renders resistant cells sensitive, as described in several studies \[[@b22-crt-2018-052]-[@b24-crt-2018-052]\]. In addition, the clinical evidence of *EGFR* co-amplification as a resistance mechanism to other MET kinase inhibitor existed in *MET*-amplified esophagogastric cancer \[[@b25-crt-2018-052]\]. One of our resistant cell lines (EBC-CR2) also was sensitive to the combined treatment. Interestingly, phosphorylation of EGFR in the EBC-CR2 cell line was increased by capmatinib in a dose-dependent manner, in contrast to the parental EBC-1 cell line. Therefore, we assumed that MET and EGFR kinase may be activated via heterodimer formation and the ability of the main cell signaling pathway to freely alternate between MET and EGFR. The EGFR pathway was mainly activated in the presence of MET-TKI and the MET pathway was activated in the presence of EGFR-TKI because of heterodimer interactions. EBCCR2 cells displayed the most MET-EGFR heterodimerization compared to the parental and other resistant cell lines, as previously mentioned. EGFR heterodimerization as resistant mechanism has been reported in some RTK inhibitors \[[@b26-crt-2018-052],[@b27-crt-2018-052]\], but not in MET-TKI. These results suggest that heterodimer can be acquired mechanism of MET-TKI for the first time. Presumably, physical interaction between MET and EGFR might facilitate the formation of MET-EGFR heterodimer or trans-phosphorylation \[[@b28-crt-2018-052]\]. In addition, effective suppression of cell proliferation in response to combined treatment supports combined therapy with MET and EGFR inhibitors as a potential therapeutic strategy for MET-TKI acquired resistance in cancer patients.

EGFR phosphorylation was inhibited by capmatinib in the parental EBC-1 cell line, but not in the EBC-CR1 cell line ([Fig. 2C](#f2-crt-2018-052){ref-type="fig"}). This result suggested that the EGFR signal of EBC-CR1 was independent of the MET signal. The survival signal in EBC-CR1 cells had completely shifted from MET to EGFR, because a single treatment with afatinib effectively inhibited downstream signaling and cell proliferation. Intriguingly, EBC-CR1 cells, which were completely EGFR-dependent, became resistant to afatinib via *PIK3CA* amplification by culture in continuous high concentrations of capmatinib as EBCCR3 cells ([Fig. 3A](#f3-crt-2018-052){ref-type="fig"} and [B](#f3-crt-2018-052){ref-type="fig"}). Genetic alteration of *PIK3CA* frequently co-occurs with other oncogenic alterations including MET \[[@b29-crt-2018-052]\]. For example, concurrent *PIK3CA* mutation and the *MET* exon 14-skipping mutation, which results in constitutive activation of MET, result in primary resistance to MET-TKIs \[[@b30-crt-2018-052],[@b31-crt-2018-052]\]. In the case of EBC-CR3 cells, *PIK3CA* amplification might be an important mechanism of acquired resistance to EGFR-TKI beyond MET-TKI resistance, which was demonstrated by the independence of EBC-CR1 cells from the MET kinase signal.

Despite exposure to similar final concentrations of capmatinib (EBC-CR2, 2.2 μmol/L; and EBC-CR3, 2.4 μmol/L), EGFR/MET co-dependent EBC-CR2 cells consistently showed sensitivity to the combination of capmatinib with afatinib. In contrast, EBC-CR3 cells acquired additional resistant mechanism of *PIK3CA* amplification. Based on this observation, a possible explanation for resistance is that EGFR-MET heterodimerization increased the cells' genetic stability or had a higher threshold concentration to induce a genetic change; thus, a genetic alteration was not required in EBC-CR2 cells. Anticancer drugs promote chromosomal instability by inducing fragile sites in chromosomes that lead to amplification events \[[@b32-crt-2018-052]\]. In addition, we observed that EBC-CR3 cells had less DNA repair-related gene expression than EBC-CR1 ([Table 2](#t2-crt-2018-052){ref-type="table"}, [S3A Fig.](#SD3-crt-2018-052){ref-type="supplementary-material"}). AKT overactivation might suppress DNA repair in EBC-CR3 cells like a previous study \[[@b33-crt-2018-052]\]. However, it is unknown whether DNA repair-related genes clearly contribute to capmatinib resistance and further study may be necessary to investigate the role of DNA repair genes as a capmatinib resistance mecahnism. Capmatinib had less of an effect on the unconstrained survival signal change in response to RTK inhibitors in EBC-CR2 cells. In contrast to EBC-CR2 cells, EBC-CR1 cells relied on ligand-dependent activation, which was less stable resistant mechansism to kinase inhibitor than heterodimerization. Therefore, a secondary event was required to increase the stability of the cells against potent MET inhibition, and shift the cells toward a *MET*-independent survival signal. Afatinib plus BYL719 effectively inhibit *PIK3CA*-amplified EBC-CR3 cells by the down-regulation of phosphorylated AKT signal that is a downstream effector of PI3K signal. Taken together, although treatment schedules or drug concentrations were similar, *in vitro* drug-resistant models showed heterogeneous resistance mechanisms in various resistant clones \[[@b34-crt-2018-052]\] like patients who have heterogenous resistance mechanisms \[[@b35-crt-2018-052]\].

In conclusion, our findings suggested that a single cell line can develop several types of EGFR-dependent mechanisms of resistance to MET-TKIs in *MET*-amplified NSCLC cell lines. One mechanism involved an increase in ligand and receptor expression. Indeed, we found increased *EGFR* and *HBEGF* mRNA expression or MET-EGFR heterodimer formation, which resulted in sensitivity of EBC-CR2 cells to combined therapy, as mechanisms to promote acquired resistance. The most interesting finding was that capmatinib treatment resulted in a shift from capmatinib resistance to afatinib resistance via *PIK3CA* amplification.

Because cancers become resistant to MET-TKI in clinical settings, it is important to understand TKI-resistance mechanisms in preclinical and clinical studies. Therefore, our results highlighted the relationship between MET, EGFR and additional altered oncogenes such as *PIK3CA* in the context of therapeutic strategies involving kinase inhibitors in capmatinib-resistant NSCLC cells.

Future efforts should be directed to prove the resistant mechanisms through an *in vivo* model as well as clinical data from *MET*-amplified NSCLC that acquires resistance to capmatinib (NCT02414139).
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![Molecular characterization of capmatinib-resistant cell lines. (A) Capmatinib-resistant cell lines (EBC-CR1, EBC-CR2, and EBC-CR3) were derived from EBC-1, which is a non-small cell lung cancer cell line that harbors mesenchymal-epithelial transition factor (*MET*) amplification. Cell lines were treated with capmatinib and crizotinib for 72 hours and growth inhibition was determined by cell viability assay (Ez-cytox). Tests were performed as three independent experiments. The EBC-CR1, -CR2, and -CR3 cell lines showed resistance to capmatinib and cross-resistance to crizotinib. (B) The resistant cell lines showed significant *MET* copy number loss after long-term treatment with capmatinib (^\*^p \< 0.05). *MET* copy number was confirmed by quantitative polymerase chain reaction. hgDNA, human genomic DNA (C) Capmatinib-resistant cells had persistent expression of phosphorylated ERK1/2 and AKT in the presence of capmatinib. EBC-1 and the resistant cell lines were treated with capmatinib at 1 μmol/L for 2 hours then analyzed by Western blot. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the loading control for the Western blot. (D) Hierarchical clustering analysis of the resistant cell lines revealed a cluster containing seven receptor tyrosine kinases (RTKs) that was increased in all resistant cell lines. The values for clustering analysis fulfilled the requirements of normalized read counts (log2) \> 6 and p \< 0.05. The fold changes in expression of these RTKs are indicated in Table 1. Each color represents relative gene expression with the highest expression as red, lowest expression as green, and median expression as black.](crt-2018-052f1){#f1-crt-2018-052}

![Shift from mesenchymal-epithelial transition factor (MET) to epidermal growth factor receptor (EGFR) kinase pathway in EBC-CR1. (A) EBC-1 and resistant cell lines were treated with afatinib for 72 hours. The 50% inhibitory concentrations (IC~50~) were calculated using Sigma Plot 12.0; results are indicated as mean±standard deviation. (B) Heparin-binding epidermal growth factor‒like growth factor (HBEGF) expression was measured by quantitative reverse transcription polymerase chain reaction in three independent experiments. HBEGF expression was increased in the EBC-CR1 cell line compared to the parental and other capmatinib-resistant cell lines (^\*\*^p \< 0.01). (C) For Western blot, EBC-1 and EBC-CR1 cells were treated with serial 10-fold dilutions ranging from 0.1 to 1 μmol/L of capmatinib with or without afatinib at 1 μmol/L for 24 hours. EBC-CR1 showed almost complete dependency on downstream signaling due to afatinib treatment with or without capmatinib. Phosphorylation of AKT and ERK1/2 was efficiently inhibited by capmatinib in EBC-1 cells. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.](crt-2018-052f2){#f2-crt-2018-052}

![Combined treatment with capmatinib and afatinib effectively inhibited phosphorylation of downstream signaling and proliferation in EBC-CR2 cells. (A) For Western blot, EBC-CR2 cells were treated with increasing concentrations of capmatinib with or without afatinib at 1 μmol/L for 24 hours. Capmatinib significantly increased epidermal growth factor receptor (EGFR) phosphorylation in a dose-dependent manner. The combination of capmatinib with afatinib at 1 μmol/L effectively inhibited phosphorylation of AKT and ERK at a low concentration of capmatinib, 100 nmol/L. (B) The heterodimerization of receptor tyrosine kinases was analyzed by co-immunoprecipitation. Although immunoprecipitation (IP) with mesenchymal-epithelial transition factor (MET) showed EGFR-MET interactions in EBC-CR1, 2, and 3 cells, IP with EGFR showed an interaction between EGFR and MET only in EBC-CR2 cells. Therefore, EBC-CR2 cells had more dominant EGFR-MET heterodimers than the other resistant cell lines. (C) EBC-CR2 cells treated with capmatinib, afatinib, and capmatinib with afatinib at 0.1 μmol/L, respectively, for 72 hours. Treatment with the combination of capmatinib with afatinib synergistically inhibited EBC-CR2 cell proliferation.](crt-2018-052f3){#f3-crt-2018-052}

![*PIK3CA* amplification in EBC-CR3, resulting to afatinib-resistance and schematic model of resistant mechanisms to capmatinib in *MET*-amplified non-small cell lung cancer (NSCLC) cell lines. (A) Treatment of EBC-CR3 cells with afatinib, BYL719, and BYL719 with afatinib at 0.1 μmol/L, respectively, for 72 hours. BYL719 with afatinib synergistically inhibited proliferation of EBC-CR3 cells. (B) *PIK3CA* copy numbers in the cell lines were measured by quantitative polymerase chain reaction. Compared to the other cell lines and the human genomic DNA control, *PIK3CA* was amplified in the EBC-CR3 cell line (^\*\*^p \< 0.01). (C) Treatment of EBC-CR3 cells with afatinib 500 nmol/L, BYL719 1 μmol/L, or BYL719 with afatinib at 500 nmol/L, respectively, for 24 hours. The combination of BYL719 with afatinib completely inhibited AKT phosphorylation. (D) In a drug-sensitive cell line harboring *MET* amplification, cell proliferation and survival signals are highly dependent on constitutively activated MET kinase without ligand binding and/or homodimerization. In addition, MET activates the epidermal growth factor receptor (EGFR) signal pathway via multiple mechanisms. In contrast, the MET pathway cannot act as a survival signal and alternative pathways must be activated in capmatinib-resistant cells. We confirmed three different mechanisms of resistance to capmatinib in MET-dependent NSCLC cell lines. (1) heterodimerization between MET and EGFR, (2) increased EGFR and EGF-like growth factor (HBEGF) expression; and (3) *PIK3CA* amplification via activated EGFR-dependent PIK3CA stimulation, resulting in afatinib resistance. Each mechanism has different molecular characteristics and therapeutic strategies. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PI3K, phosphoinositide-3-kinase; mTOR, mammalian target of rapamycin.](crt-2018-052f4){#f4-crt-2018-052}

###### 

Differential expression of genes encoding RTKs between EBC-1 and resistant cells

  Gene       Fold change            
  ---------- ------------- -------- --------
  *KIT*      24.250        73.500   28.250
  *EFEMP1*   10.200        32.369   17.131
  *INSR*     4.252         2.194    6.600
  *CD74*     4.767         13.317   4.481
  *IGF1R*    5.546         7.636    3.350
  *EGFR*     4.001         4.160    5.189
  *MET*      0.824         0.900    0.936

Gene expression profiles were measured by 3′ mRNA sequencing. RTK, receptor tyrosine kinase; EFEMP1, EGF containing fibulin like extracellular matrix protein 1; INSR, insulin receptor; IGF1R, insulin like growth 1 receptor; EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition factor.

###### 

Fold change of downregulated DNA repair gene expression on gene ontology analysis

  Gene        Fold change           
  ----------- ------------- ------- -------
  *ASTE1*     1.124         0.587   0.497
  *DCLRE1A*   0.928         0.329   0.419
  *DNA2*      0.482         0.086   0.210
  *ESCO2*     1.025         0.113   0.229
  *EXO1*      1.055         0.500   0.500
  *INO80C*    0.371         0.424   0.181
  *PCNA*      0.879         0.360   0.425
  *PPP5C*     1.216         0.622   0.437
  *RPS3*      2.433         1.232   1.157
  *TP73*      0.343         0.054   0.086
  *TRIP13*    1.091         0.130   0.481
  *UBE2NL*    1.721         0.318   0.604
  *XRCC3*     0.633         0.284   0.302
  *UNG*       0.771         0.235   0.329

ASTE1, asteroid homolog 1; DCLRE1A, DNA cross-link repair 1A; DNA2, DNA replication helicase/nuclease 2; ESCO2, establishment of sister chromatid cohesion N-acetyltransferase 2; EXO1, exonuclease 1; INO80C, INO80 complex subunit C; PCNA, proliferating cell nuclear antigen; PPP5C, protein phosphatase 5 catalytic subunit; RPS3, ribosomal protein S3; TP73, tumor protein p73; TRIP13, thyroid hormone receptor interactor 13; UBE2NL, ubiquitin conjugating enzyme E2 N like; XRCC3, X-ray repair cross complementing 3; UNG, uracil DNA glycosylase.
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